Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.

@article{Ratcliffe2017AgreementBP,
  title={Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.},
  author={Marianne Jennifer Ratcliffe and Alan D. Sharpe and Anita Midha and Craig John Barker and Marietta L. J. Scott and Paul M Scorer and Hytham Al-Masri and Marlon Rebelatto and Jill Walker},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 14},
  pages={
          3585-3591
        }
}
Purpose: Immunotherapies targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) demonstrate encouraging antitumor activity and manageable tolerability in non-small cell lung cancer (NSCLC), especially in patients with high tumor PD-L1 expression, as detected by companion or complementary diagnostic assays developed for individual agents. A laboratory is unlikely to use multiple assay platforms. Furthermore, commercially available diagnostic assays are not… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 78 CITATIONS, ESTIMATED 54% COVERAGE

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy.

  • Critical reviews in oncology/hematology
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2017
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 26 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2017
VIEW 2 EXCERPTS